Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors-Reference-Cited by-同舟云学术

Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Published:2016-01 Issue:1 Volume:15 Page:8-14
ISSN:1109-3099
Container-title:Hormones
language:en
Short-container-title:Hormones

Author:

Achimastos Apostolos,Alexandrides Theodoras,Alexopoulos Dimitrios,Athyros Vasilios,Bargiota Alexandra,Bilianou Eleni,Chrysochoou Christina,Drogari Evridiki,Elisaf Moses,Ganotakis Emanouel,Goudevenos Ioannis,Ioannidis Ioannis,Kolovou Genovefa,Kotsis Vasilios,Lekakis Ioannis,Liberopoulos Evangelos,Melidonis Andreas,Nikolaou Vasilios,Ntaios George,Papanas Nikolaos,Pappas Stavros,Pitsavos Christos,Rallidis Loukianos,Richter Dimitrios,Skoumas Ioannis,Tentolouris Nicolaos,Tousoulis Dimitrios,Tselepis Alexandras,Tsioufis Konstantinos,Tziakas Dimitrios,Tziomalos Konstantinos,Vardas Panagiotis,Vlachopoulos Charalabos,Vlahakos Dimitrios

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1007/BF03401398/fulltext.html

Reference38 articles.

1. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ, 2008 Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 49: 394–398.

2. Elisaf M, Liberopoulos E, Pitsavos C, et al, 2014 Updated guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia-2014. Hellenic J Atheroscler 5: 151–163 [in Greek]

3. European Association for Cardiovascular Prevention & Rehabilitaiton, Reiner Z, Catapano AL, De Backer G, et al, 2011 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32: 1769–1818.

4. Stone NJ, Robinson JG, Lichtenstein AH, et al, 2014 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129: Supple 2: 1–45.

5. Anderson TJ, Gregoire J, Hegele RA, et al, 2013 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29: 151–167.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023;Atherosclerosis Plus;2024-03

2. Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study;Hellenic Journal of Cardiology;2023-11

3. Efficacy and safety of PCSK9 inhibitors in patients with diabetes: A systematic review and meta-analysis;Nutrition, Metabolism and Cardiovascular Diseases;2023-09

4. Treatment of Dyslipidaemia in Children;Biomedicines;2021-08-24

5. Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience;Archives of Medical Research;2021-05